drugset
drugset / Trial / NCT02433847

Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects

NCT02433847 ↗

Phase 4 Unknown 20 enrolled Seoul National University Hospital
NaSingle-groupOpen-labelTreatment

Summary

Effect of mosapride 30mg/day on the small bowel and colon transit time in patients with chronic constipation or constipated irritable bowel syndrome.

Timeline

Start
2015-05
Primary completion
2016-04
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Mosapride Small molecule 30 mg —

Indications

constipation disorder irritable bowel syndrome